Tirasemtiv not checked

Cytokinetics · CK-2017357

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Amyotrophic Lateral Sclerosis (ALS)
Main trialPhase 3
“The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv in ALS (CY 4031).”In the company’s words, NCT02936635 on ClinicalTrials.gov
Other names
CK-2017357

Other drugs for Amyotrophic Lateral Sclerosis (ALS)

All 48 drugs for Amyotrophic Lateral Sclerosis (ALS)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Completed 26 Oct 2018 A Study for Patients Who Completed VITALITY-ALS (CY 4031)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tirasemtiv

Following is part of Solo: you see every change to Tirasemtiv the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in